The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA ...
(RTTNews) - Moderna, Inc. (MRNA) announced Friday that the U.S. Food and Drug Administration's review of the Biologics License Application or BLA for mRNA-1345, its investigational respiratory ...
First, a bit of background on Moderna's RSV candidate. RSV generally causes cold-like symptoms, but the virus could be severe ...
Moderna (NASDAQ:MRNA) announced Friday that the U.S. Food and Drug Administration (FDA) has pushed back its timeline to complete the review of its marketing application for mRNA-1345, a messenger ...
CAMBRIDGE, MA - The U.S. Food and Drug Administration (FDA) has notified biotechnology company Moderna , Inc. (NASDAQ:MRNA) that it will not meet the May 12, 2024, deadline to complete the review ...